Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: pantano f. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Molecular prognostic factors in patients with pancreatic cancer.
Tonini G, Pantano F, Vincenzi B, Gabbrielli A, Coppola R, Santini D. Tonini G, et al. Among authors: pantano f. Expert Opin Ther Targets. 2007 Dec;11(12):1553-69. doi: 10.1517/14728222.11.12.1553. Expert Opin Ther Targets. 2007. PMID: 18020978 Review.
Cetuximab: from bench to bedside.
Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Vincenzi B, et al. Among authors: pantano f. Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. doi: 10.2174/156800910790980241. Curr Cancer Drug Targets. 2010. PMID: 20088790 Review.
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.
Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. Santini D, et al. Among authors: pantano f. J Cell Physiol. 2011 Mar;226(3):780-4. doi: 10.1002/jcp.22402. J Cell Physiol. 2011. PMID: 20857484
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G. Santini D, et al. Among authors: pantano f. PLoS One. 2011 Apr 29;6(4):e19234. doi: 10.1371/journal.pone.0019234. PLoS One. 2011. PMID: 21559440 Free PMC article.
New targets, new drugs for metastatic bone pain: a new philosophy.
Pantano F, Zoccoli A, Iuliani M, Lanzetta G, Vincenzi B, Tonini G, Santini D. Pantano F, et al. Expert Opin Emerg Drugs. 2011 Sep;16(3):403-5. doi: 10.1517/14728214.2011.588600. Epub 2011 May 31. Expert Opin Emerg Drugs. 2011. PMID: 21623686
135 results